OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson Sells 7,255 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson sold 7,255 shares of OmniAb stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total transaction of $26,625.85. Following the completion of the sale, the chief financial officer now owns 206,211 shares of the company’s stock, valued at approximately $756,794.37. The trade was a 3.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

OmniAb Trading Up 0.3 %

Shares of OmniAb stock opened at $3.67 on Thursday. OmniAb, Inc. has a 1-year low of $3.10 and a 1-year high of $6.55. The business has a 50-day moving average price of $3.49 and a two-hundred day moving average price of $3.91. The company has a market cap of $518.28 million, a P/E ratio of -5.92 and a beta of -0.12.

Institutional Trading of OmniAb

Large investors have recently modified their holdings of the stock. Hsbc Holdings PLC bought a new position in shares of OmniAb during the 4th quarter worth about $38,000. Choreo LLC purchased a new position in shares of OmniAb during the fourth quarter valued at approximately $41,000. Rangeley Capital LLC purchased a new position in OmniAb during the 4th quarter worth $41,000. KLP Kapitalforvaltning AS purchased a new position in OmniAb during the fourth quarter worth about $49,000. Finally, CWC Advisors LLC. purchased a new position in shares of OmniAb in the 3rd quarter worth approximately $54,000. Institutional investors and hedge funds own 72.08% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on OABI. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reissued a “buy” rating and issued a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.